William Blair Upgrades DocuSign (DOCU) Stock on IAM Platform’s Potential
Software company DocuSign (DOCU) scored a rating upgrade from Hold to Buy from William Blair, thanks to the optimism about ...
William Blair Reaffirms Their Hold Rating on Science Applications (SAIC)
William Blair analyst Louie DiPalma maintained a Hold rating on Science Applications (SAIC – Research Report) today. The company’s shares ...
What is William Blair’s Estimate for Sprinklr Q1 Earnings?
Equities research analysts at William Blair issued their Q1 2026 earnings estimates for shares of Sprinklr in a note issued ...
William Blair Issues Negative Estimate for Duluth Earnings
Equities research analysts at William Blair cut their Q4 2026 earnings estimates for shares of Duluth in a research report issued to clients and investors on Thursday, March 13th. William Blair ...
Incyte Is Today’s Worst S&P 500 Stock. Here’s Why.
The biopharmaceutical company announces positive results from two skin disease treatment studies. But Wall Street doesn’t ...
Investor's Business Daily on MSN3h
Incyte Plummets 13% As Skin Disease Drug Looks 'Viable, But Not Competitive'
Incyte's skin disease treatment looks "viable, but not competitive with biologics," an analyst said Monday as Incyte stock crashed.
Finbold1h
Analyst uprgades Palantir stock
A Wall Street analyst believes Palantir's (NASDAQ: PLTR) expanding artificial intelligence (AI) ecosystem, marked by major ...